R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

Inclusion Criteria

• Age ≥ 18 and ≤ 75 years.
• Patients with follicular lymphoma grade 1, 2 or 3a, CD20 +, histologically confirmed lymph node biopsy or tissue. Be accepted diagnosis in bone marrow if no accessible lymph nodes and whether it has discarded the mantle LLC, and NHL.
• Follicular lymphoma patients treated with the combination of rituximab and chemotherapy in first line, which have been refractory or relapsed after having achieved any responses to this first line of pretreatment (excluding radiotherapy).
• ECOG ≤ 2.
• Signed written informed consent.

Exclusion Criteria

• Clinical suspicion or documentation of histological transformation.
• Have received prior chemotherapy scheme, first line without Rituximab.
• Prior autologous or allogeneic.
• CNS infiltration by LF (primary CNS lymphoma or lymphomatous meningitis).
• Past or active Hepatitis B (at least one of the following markers HBsAg, HBe Ag, anti-HBc, HBV DNA)
• HCV infection. HIV infection or other conditions of serious immunosuppression.
• Previous neoplasms except non-melanoma skin cancer of the cervix or adequately treated.
• Cardiac function in cardiac patient known or prior treatment with anthracyclines with EF 1.5 x Upper Limit of Normal, LSN) or a creatinine clearance 2 x ULN) were not related to lymphoma.
• Women who are nursing or pregnant. Women of childbearing potential will be included prior pregnancy test serum / urine negative. Use effective contraception to be kept for 1 year after cessation of rituximab.
• Patients with heart disease, pulmonary, neurological, psychiatric or severe metabolic and not secondary to lymphoma.
• Severe acute or chronic infection in activity.
• Any other concurrent medical or psychological comorbidity that might interfere with participation in this study.